Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Cell Cycle Regulation Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for SKP2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SKP2 Recombinant Protein (WT/Mutant) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View SKP2 Products |
| Gene Delivery | SKP2 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View SKP2 Products |
| Benchmark Ab | Anti-SKP2 Recombinant Antibody Recombinant positive control for assay validation. |
View SKP2 Products |
| Validator | SKP2 siRNA Set For knockdown verification. |
View SKP2 Products |
| Related Target A | CKS1B Essential accessory protein that mediates SKP2 binding to its primary substrate, p27 (Kip1). |
View CKS1B Products |
| Related Target B | CDKN1B (p27 Kip1) The primary downstream substrate of the SCF-Skp2 ubiquitin ligase complex. |
View CDKN1B Products |
| Related Target C | SKP1 Core adaptor protein of the SCF (SKP1-CUL1-F-box) E3 ubiquitin ligase complex. |
View SKP1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Reconstitution of the SKP2-CKS1B interface for PPI screening | Co-expressed or highly pure individual SKP2 and CKS1B proteins with verified sequence and low endotoxin. |
| In vitro ubiquitination assay replication | Highly active SKP1, CUL1, and CDKN1B (p27) proteins strictly verified by SDS-PAGE and Mass Spec. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live SKP2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for SKP2 therapeutics is intensifying, with major players shifting focus from traditional mAbs to small molecule protein-protein interaction (PPI) inhibitors and targeted protein degraders (PROTACs). As first-generation therapies reach the clinic, the next wave of R&D is targeting the disruption of the SKP2-CKS1B interface to selectively stabilize p27 and arrest the cell cycle in refractory cancers.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (PPI Inhibitors) | Academic Consortia, Preclinical Biotech | Prostate Cancer, Breast Cancer, Lymphoma | TR-FRET/AlphaScreen binding assays (Need highly pure SKP2 and CKS1B proteins) |
| PROTACs (SKP2 Degraders) | Targeted Protein Degradation (TPD) Developers | Solid Tumors, CDK4/6-resistant Cancers | Ubiquitination and degradation validation (Need SKP2, SKP1, CUL1, and p27 proteins) |
| Combination Therapies (with CDK4/6i) | Clinical-stage Oncological Biotechs | Refractory HR+ Breast Cancer | Cell line construction and stable overexpression (Need SKP2 Lentivirus Premade Particles) |